NCT04708067 2026-03-05
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT03942328 2026-02-24
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT06178588 2026-02-24
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT03212274 2026-02-19
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03878095 2025-11-17
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06058663 2025-10-20
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Recruiting
NCT07007832 2025-06-11
Bile Omics for Diagnosing Indeterminate Biliary Strictures
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting
NCT03201458 2024-04-05
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed